, in which the seropositivity in pregnant women with Bad Obstetric History (BOH) was found to be 12.5% (13/104) and women without BOH was found to be 10.52% (4/38). The statistical association of any one of the TORCH infections with previous obstetric history was significant (p<0.05). The seropositivity rate was the highest for HSV infection followed by Rubella, CMV and T. gondii.
In developing countries like Nepal, where most of the women belong to the low socio-economic group, may be exposed to one or more of the TORCH agents that may lead to serious congenital malformations. Therefore, appropriate intervention measures, early diagnosis and treatment of TORCH infection have to be carried out to reduce these infections during pregnancy and their effect on outcome of pregnancy. Studies on epidemiology of TORCH in Nepalese people are increasing yet the results obtained from these studies do not provide actual seroprevalence, as they are case oriented rather than population oriented and, in addition, are hospital-based studies. However, these handfuls of studies are suggestive for the presence of immunity to TORCH agents in Nepalese population. This study aims to determine current status of TORCH and assess risk factors among immunocompromised patients visiting National Public Health Laboratory (NPHL), Teku during the study period. At NPHL, the scheme for diagnosing the infection is done through TORCH panel which is solely dependent upon the detection of IgM antibodies against those organisms, and only few of them are subjected further for the analysis of IgG antibodies in serum sample. The detection of only IgM antibodies limits the establishment of prevalence among people. This study aims to determine the prevalence of anti-TORCH antibodies in suspected serum samples and establish the relation of risk factors with the infection. The study compares and contrasts the status of infection in suspected individuals visiting NPHL.
coupled with fetal monitoring. The knowledge on these diseases will enable the clinicians to provide appropriate counseling service to the mothers thus providing preventive measures to avoid these infections, and will aid in counseling parents on the potential for adverse fetal outcomes when these infections are present (Stegmann and Carey, 2002) . The TORCH agents are responsible for very frequent infection in HIV positive patients with progressively lowered immunity. Such individuals required to be diagnosed at an early stage. Hence, treating clinicians are requested to investigate the patients accordingly to modify their treatment regimens and necessary prophylaxis as required. Many sensitive and specific tests are available for serological diagnosis of TORCH complex (Newton, 1999) . ELISA for IgM antibodies against these infections is highly sensitive and specific (Malhotra and Bhardwaj, 1991) . 
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Materials and Methods
Suspected Case: Any generalized rash illness of acute onset that does not meet the criteria for probable or confirmed rubella or any other illness. Probable: In the absence of a more likely diagnosis, an illness characterized by all of the following i.e. Acute onset of generalized maculopapular rash, temperature greater t h a n 9 9 . 0°F o r 3 7 . 2°C , a r t h r a l g i a , a r t h r i t i s , l y m p h a d e n o p a t h y, o r c o n j u n c t i v i t i s , l a c k o f epidemiologic linkage to a laboratory confirmed case of rubella and non-contributory or no serologic or virologic testing. Confirmed: A case with or without symptoms who has laboratory evidence of rubella infection confirmed by one or more of the following laboratory tests i.e. isolation of rubella virus; or detection of rubellavirus specific nucleic acid by polymerase chain reaction; or IgG seroconversion or a significant rise between acute- Figure 1 ). Figure 2) .
Figure 1: Age wise distribution of TORCH suspects cases at NPHL
Almost all of the population representing the women was from childbearing age whereas male population followed diagnosis only after the suspicion of the disease. Figure 3 ).
Figure 3:Seroprevalence of TORCH IgM antibodies TORCH Infection among HIV Positive Patients:
Among 314 patients, 11 patients (two female; nine male) were living with HIV/AIDS.The seropositivity rates among the suspects were 9.09% (1/11) for T.gondii, 20%
(2/10) for Rubella, 20% (2/10) for CMV and 10% (1/10) for HSV. The overall seropositivity was 18.18% (Figure 4) . (Lamichhane et al, 2015) . The highest number of female patients was found in the age group 21-30 followed by age group 31-40 years. This is probably because of the fact that females of these age groups (21-40 years) are of child bearing and screened for antibodies against TORCH agents at their prenatal visits. Nowadays, in addition to the higher prevalence rate, the trend of recommendation for pregnant women to undergo the diagnosis for TORCH is increasing.
Women with child bearing age group are recommended by doctor for the diagnosis even when symptoms in relation to TORCH infections are not observed. The increasing trend, off course, is a good signal for maternal health and is reflected in the study also. The number of male patients was higher in the age group (31-40 year). The difference in trend is probably because of the fact that most of the male patients have trend to visit lab only after the onset of the symptoms either related to TORCH or other else. Most of the patients have habit to visit only after undergoing illnesses (Rai et al, 2011) . Toxoplasma, Rubella, CMV and HSV respectively were reported on women with spontaneous abortions (Guddy et al, 2015) .
The present study result was found highly deviated than other similar studies due to the fact that NPHL is a tertiary care center and most of the patients had habit of visiting the center only after the onset of the problems. Most of the patients were found with previous disease history. Only a small fraction of our study was focused to detect IgG antibodies against the agents. Therefore, IgG persists for long time after an infection is established. This could be the principal reason for the pattern. None of the study has done yet to compare the sensitivity of the ELISA and CLIA. The sensitivity issue could be another reason for this large deviation.In another study done in 2012 at Dhulikhel, Kathmandu University, prevalence rates were estimated as 77.9% for T. gondii, 86.8% for Rubella, 51.9% for CMV and 84.4% for HSV (Acharya et al, 2014) . The finding of this study was comparable to our study. Although the result is highly deviated for Toxoplasma and CMV, rest of the infections had higher prevalence rate. The highest seropositivity for Rubella can again be acknowledged for the previous immunization practice in Nepal.Although, nearly half of the Nepalese are T. gondii seropositive (Rai et al, 1998) , this study is not likely to support the established fact. This could be because of increasing awareness and sanitation practice targeted against the infection.
Seropositivity rates in relation to status of pregnancy and BOH outcomes differed significantly in our study. Almost all studies revealed higher prevalence among women in childbearing age. Various studies revealed that congenital infections caused by TORCH agents were a significant cause of neonatal mortality and childhood morbidity worldwide. In our study, the patients with negative IgM still had symptoms related to the disease and those women with negative IgM still had unfavorable pregnancy outcomes. There are more sensitive, specific and reliable methods for screening. To determine the IgG avidity, to perform TORCH tests in paired samples, molecular methods of organism identification is necessary (Owen et al, 2006) . Hence, our study also doubted the single serum assays for TORCH screening.
The main aim of this study was to determine the overall seroprevalence rate of IgM antibodies against TORCH infection. The seropositivity rates were found to be 4.20% (9/214), for T. gondii, 6.67% (13/195) for Rubella, 4.52% (11/243) for CMV and 5.15% (12/233) for HSV. In another study conducted in 2015 found prevalence of serum antibodies against TORCH infections as 18.82% for Toxoplasma, 10.07% for Rubella, 16.49% for CMV & 23.34% for HSV (Lamichhane et al, 2015) . The seropositivity rates were also far higher than our estimates. Similarly, in another study; the rates were estimated as 26.6% for Toxoplasma, 9.2% for Rubella, 17.4% for CMV & 4.6% for HSV (Pradhan, 2015) . This finding was also highly deviated from our study. In another study, the seropositivity rate was estimated as 23.2% for one or more TORCH agents. Similarly, prevalence rates of IgM antibodies were 13.7% for Toxoplasma, 4.7% for Rubella, 11.7% for CMV & 11.9% for HSV (Lamichhane et al, 2015) . Leaving behind other TORCH agents, the prevalence rate of Rubella was comparable to our study. This low rate can again be accredited to the aggressive immunization practice carrying out in national immunization program by government itself. In another study, the seropositivity rates among women with spontaneous abortions were reported as 16.3% for Toxoplasma, 3.3 % for Rubella, 2% for CMV and 3.3% for HSV (Guddy et al, 2015) . The study is comparable to our findings. The analogy could be due to the fact that the study was also carried out in tertiary care centre Tribhuvan University Teaching Hospital. These studies do not correlate with our present studies. This is because of the main reason that most of the studies are focused to pregnant women and with Bad Obstetric performance rather than overall population group. Our study found 11.97% overall seroprevalence rate of one or more TORCH agents among pregnant women. The stratified results based on individual agent, if provided, still become lower than the previous findings.
Our focus was to estimate the overall prevalence rate in pregnant women rather than stratified results on individual agents from TORCH groups. However, the seroprevalence rates among HIV positive individuals are comparable to all other studies. This is because of lowered immunity among the individuals. The infection rate among such individual is well documented. The first and foremost striking but convincing outcome of our study is the extremely low yield of IgM seropositivity as compared to that of IgG antibodies. The rate of seroconversion occurring in pregnancy has been estimated to be around 1% only (Jauniaux et al, 2006) . This low rate of detection was not surprising as few studies have suggested no detection or low detection of infection undergoing TORCH testing (Cullen et al, 1998; Leland et al, 1983) . The low rate of sero-conversion and detection might be the reason in our study behind the high sensitivity of the CLIA method over traditional ELISA method existing in our laboratories. The high yield of equivocal result might have possibilities to be reported otherwise as false positive in traditional ELISA method.
Further, the cost of the whole TORCH panel test being very high, most general population from developing countries like Nepal, cannot afford the cost. Moreover, during pregnancy, periodic monitoring is required, which aids further difficulty to the people. By including vaccination against rubella virus (MMR vaccine) in the national immunization schedule, the incidence of congenital rubella can be reduced greatly. When elimination is achieved by prevention and vaccination, this component can be deleted from the TORCH-panel investigations, thereby reducing their cost.
Conclusions
The IgM seroprevalence rates were 4.20% (9/214) for T. gondii, 5.12% (10/195) for Rubella, 4.91% (12/244) for CMV and 5.56% (13/234) for HSV. So it is recommended that previous history of pregnancy wastage and the serological reactions for TORCH infections during current pregnancy must be considered while managing BOH cases to reduce the adverse fetal outcome.
